Qaiser Bashir
M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Qaiser Bashir as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:51 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06207799 · Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple MyelomaM.D. Anderson Cancer Center · recruiting · Multiple Myeloma, Post-transplant MRD-guided Maintenance Therapy, Pre-transplant Purging · principal investigator
- Ph2NCT05091372 · Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple MyelomaM.D. Anderson Cancer Center · recruiting · Myeloma Multiple · principal investigator
- Ph2NCT04317781 · Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell TransplantM.D. Anderson Cancer Center · terminated · Blastic Plasmacytoid Dendritic Cell Neoplasm · principal investigator
- Ph1/Ph2NCT03417284 · Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell TransplantationM.D. Anderson Cancer Center · completed · Plasma Cell Myeloma · principal investigator
- N/ANCT01927718 · Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT)M.D. Anderson Cancer Center · terminated · Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:51 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in multiple myeloma, ranked by citations from NIH iCite, fetched 2026-11-12 11:51 UTC. The ranking covers the 200 most relevant of 13 PubMed records, and a shared surname and initials can bring in a namesake. All 13 on PubMed
- Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma.Br J Haematol · 2017177 citationsRCR 5.3
- Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial.Lancet Haematol · 201975 citationsRCR 3.1
- 33 citationsRCR 1.0
- Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs.Bone Marrow Transplant · 201926 citationsRCR 1.1
- 25 citationsRCR 1.4
- Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report.Biol Blood Marrow Transplant · 201922 citationsRCR 0.9
- A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma.Biol Blood Marrow Transplant · 201321 citationsRCR 0.7
- High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan.Lancet Haematol · 201719 citationsRCR 0.6
- Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study.Clin Lymphoma Myeloma Leuk · 202015 citationsRCR 0.6
- Comparative Safety, Bioavailability, and Pharmacokinetics of Oral Dexamethasone, 4-mg and 20-mg Tablets, in Healthy Volunteers Under Fasting and Fed Conditions: A Randomized Open-label, 3-way Crossover Study.Clin Lymphoma Myeloma Leuk · 202013 citationsRCR 0.7